NCCN Categories of Evidence and Consensus
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
All recommendations are category 2A unless otherwise noted.
Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN defines cancer-related fatigue as “a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning.”1 Fatigue is a common symptom in patients with cancer and is nearly universal in those receiving cytotoxic chemotherapy, radiation therapy, bone marrow transplantation, or treatment with biological response modifiers.2-4 According to a survey of 1569 patients with cancer, the symptom is experienced by 80% of individuals who receive chemotherapy and/or radiotherapy.5,6 Cancer survivors report that fatigue continues to be a disruptive symptom after treatment ends,7-14 with studies showing that 17% to 29% of cancer survivors experience persistent fatigue for years after the completion of active therapy.15,16 Persistent cancer-related fatigue affects quality of life, because individuals become too tired to fully participate in the roles and activities that make life meaningful.9,17 Disability-related issues are also relevant for cancer survivors, because obtaining or retaining disability benefits from insurers is often difficult for patients with cancer-related fatigue. Identification and management of fatigue remains an unmet need for many cancer survivors.
The specific mechanisms involved in the pathophysiology of cancer-related fatigue are unknown. Proposed mechanisms include proinflammatory cytokines, hypothalamic-pituitary-adrenal axis dysregulation, circadian rhythm desynchronization, skeletal muscle wasting, and genetic dysregulation.18-23 Several studies have focused on the cause of fatigue, especially in cancer survivors with no evidence of active disease, and have suggested that persistent immune system activation and chronic inflammatory processes may be involved.7,24-26 Evidence supporting these mechanisms is limited.
BergerAMAbernethyAPAtkinsonA. NCCN Clinical Practice Guidelines in Oncology for cancer-related fatigue. J Natl Compr Canc Netw2010;8:904–931.
CollinsJJDevineTDDickGS. The measurement of symptoms in young children with cancer: the validation of the Memorial Symptom Assessment Scale in children aged 7-12. J Pain Symptom Manage2002;23:10–16.
HenryDHViswanathanHNElkinEP. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the USSupport Care Cancer2008;16:791–801.
BowerJEGanzPADesmondKA. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol2000;18:743–753.
CromDBHindsPSGattusoJS. Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach. Oncol Nurs Forum2005;32:1131–1141.
RufferJUFlechtnerHTrallsP. Fatigue in long-term survivors of Hodgkin’s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer2003;39:2179–2186.
ServaesPVerhagenSBleijenbergG. Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol2002;13:589–598.
ServaesPVerhagenSSchreuderHW. Fatigue after treatment for malignant and benign bone and soft tissue tumors. J Pain Symptom Manage2003;26:1113–1122.
WangXSZhaoFFischMJ. Prevalence and characteristics of moderate to severe fatigue: A multicenter study in cancer patients and survivors. Cancer2014;120:425–432.
JandaMGerstnerNObermairA. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer2000;89:1322–1328.
BergerAMWielgusKHertzogM. Patterns of circadian activity rhythms and their relationships with fatigue and anxiety/depression in women treated with breast cancer adjuvant chemotherapy. Support Care Cancer2009;18:105–114.
MillerAHAncoli-IsraelSBowerJE. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol2008;26:971–982.
RichTA. Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis. J Support Oncol2007;5:167–174; discussion 176-167.
SchubertCHongSNatarajanL. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun2007;21:413–427.
AlfanoCMImayamaINeuhouserML. Fatigue, inflammation, and omega-3 and omega-6 fatty acid intake among breast cancer survivors. J Clin Oncol2012;30:1280–1287.
BowerJEGanzPAIrwinMR. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?J Clin Oncol2011;29:3517–3522.
MendozaTRWangXSCleelandCS. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer1999;85:1186–1196.
PiperBFDoddMJReamE. Improving the clinical measurement of cancer treatment-related fatigue. Better health through nursing research: international state of the science. Vol. 99. Washington, DC: American Nurses Association; 1999.
BarsevickAMDudleyWBeckS. A randomized clinical trial of energy conservation for patients with cancer-related fatigue. Cancer2004;100:1302–1310.
BrownJCHuedo-MedinaTBPescatelloLS. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomarkers Prev2011;20:123–133.
CourneyaKSMackeyJRBellGJ. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol2003;21:1660–1668.
MishraSISchererRWGeiglePM. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev2012;8:CD007566.
McMillanEMNewhouseIJ. Exercise is an effective treatment modality for reducing cancer-related fatigue and improving physical capacity in cancer patients and survivors: a meta-analysis. Appl Physiol Nutr Metab2011;36:892–903.
McNeelyMLCampbellKLRoweBH. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ2006;175:34–41.
McNeelyMLCourneyaKS. Exercise programs for cancer-related fatigue: evidence and clinical guidelines. J Natl Compr Canc Netw2010;8:945–953.
SpeckRMCourneyaKSMasseLC. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv2010;4:87–100.
DuijtsSFFaberMMOldenburgHS. Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors: a meta-analysis. Psychooncology2011;20:115–126.
EspieCAFlemingLCassidyJ. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol2008;26:4651–4658.
EpsteinDRDirksenSR. Randomized trial of a cognitive-behavioral intervention for insomnia in breast cancer survivors. Oncol Nurs Forum2007;34:E51–59.
GielissenMFMVerhagenSWitjesFBleijenbergG. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol2006;24:4882–4887.
KangasMBovbjergDHMontgomeryGH. Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull2008;134:700–741.
MustianKMMorrowGRCarrollJK. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist2007;12(Suppl 1):52–67.
JacobsenPBDonovanKAVadaparampilSTSmallBJ. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol2007;26:660–667.
DavidsonJRWaisbergJLBrundageMDMacLeanAW. Nonpharmacologic group treatment of insomnia: a preliminary study with cancer survivors. Psychooncology2001;10:389–397.
FlemingLRandellKHarveyCJEspieCA. Does cognitive behaviour therapy for insomnia reduce clinical levels of fatigue, anxiety and depression in cancer patients? [published online ahead of print January 23, 2014]. Psychooncology. doi: 10.1002/pon.3468.
QuesnelCSavardJSimardS. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol2003;71:189–200.
SavardJSimardSIversHMorinCM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol2005;23:6083–6096.
DirksenSREpsteinDR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs2008;61:664–675.
BergerAMVonEssenSKhunBR. Feasibilty of a sleep intervention during adjuvant breast cancer chemotherapy. Oncol Nurs Forum2002;29:1431–1441.
MorgenthalerTKramerMAlessiC. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep2006;29:1415–1419.
LowerEEFleishmanSCooperA. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage2009;38:650–662.
GongSShengPJinH. Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis. PLoS One2014;9:e84391.
MorrowGRGilliesLJHickokJT. The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed [abstract]. J Clin Oncol2005;23(Suppl 16):Abstract 8012.
KaleitaTAWellischDKGrahamCA. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors [abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 1503.
BartonDLLiuHDakhilSR. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst2013;105:1230–1238.